EFFICACY AND SAFETY OF VWF CONCENTRATES IN A COHORT OF 93 PATIENTS WITH TYPE 3 VON WILLEBRAND DISEASE ENROLLED IN 3WINTERS-IPS: RESULTS OF THE 2-YEAR PROSPECTIVE CLINICAL OBSERVATION

被引：0
|
作者：
Peake, I. R. [1 ]
Federici, A. B. [2 ]
机构：
[1] Univ Sheffield, Dept Dent & Hlth, Fac Med, Sheffield, S Yorkshire, England
[2] Univ Milan, L Sacco Univ Hosp, Hematol & Transfus Med, Milan, Italy
来源：
HAEMOPHILIA | 2023年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PO-44
引用
收藏
页码：46 / 47
页数：2
相关论文
共 50 条
  • [41] Clinical Efficacy and Safety Versus Biological Response of Desmopressin (DDAVP) In Inherited Von Willebrand Disease (VWD) Types 1 and 2: Initial Results From the International Study Group on DDAVP In VWD In a Cohort of 229 Patients
    Federici, Augusto B.
    Iorio, Alfonso
    Castaman, Giancarlo
    BLOOD, 2010, 116 (21) : 110 - 111
  • [42] Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2-year results from two pivotal phase 3 studies
    Kulasekararaj, Austin G.
    Griffin, Morag
    Langemeijer, Saskia
    Usuki, Kensuke
    Kulagin, Alexander
    Ogawa, Masayo
    Yu, Ji
    Mujeebuddin, Arshad
    Nishimura, Jun-ichi
    Lee, Jong Wook
    de Latour, Regis Peffault
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2022, 109 (03) : 205 - 214
  • [43] EFFICACY AND SAFETY OF TOCILIZUMAB (TCZ) IN PATIENTS WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA): 2-YEAR DATA FROM TENDER, A PHASE 3 CLINICAL TRIAL
    De Benedetti, F.
    Brunner, H.
    Ruperto, N.
    Kenwright, A.
    Devlin, C.
    Calvo, I.
    Cuttica, R.
    Ravelli, A.
    Schneider, R.
    Eleftheriou, D.
    Wouters, C.
    Xavier, R.
    Zemel, L.
    Baildam, E.
    Burgos-Vargas, R.
    Dolezalova, P.
    Garay, S. M.
    Joos, R.
    Grom, A.
    Wulffraat, N.
    Zuber, Z.
    Zulian, F.
    Lovell, D.
    Martini, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 425 - 425
  • [44] A 2-year phase 3 study of safety and efficacy of etanercept 50 mg twice weekly in patients with psoriasis: Results from the 3-month double-blind period
    Tyring, S
    Rosoph, L
    Toth, D
    Zitnik, R
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 52 (03) : P171 - P171
  • [45] Assessment of the Olfactory Function in Italian Patients with Type 3 von Willebrand Disease Caused by a Homozygous 253 Kb Deletion Involving VWF and TMEM16B/ANO2
    Cenedese, Valentina
    Mezzavilla, Massimo
    Morgan, Anna
    Marino, Renato
    Ettorre, Cosimo Pietro
    Margaglione, Maurizio
    Gasparini, Paolo
    Menini, Anna
    PLOS ONE, 2015, 10 (01):
  • [46] Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
    Rovin, Brad H.
    Barratt, Jonathan
    Heerspink, Hiddo J. L.
    Alpers, Charles E.
    Bieler, Stewart
    Chae, Dong-Wan
    Diva, Ulysses A.
    Floege, Juergen
    Gesualdo, Loreto
    Inrig, Jula K.
    Kohan, Donald E.
    Komers, Radko
    Kooienga, Laura Ann
    Lafayette, Richard
    Maes, Bart
    Malecki, Robert
    Mercer, Alex
    Noronha, Irene L.
    Oh, Se Won
    Peh, Chen Au
    Praga, Manuel
    Preciado, Priscila
    Radhakrishnan, Jai
    Rheault, Michelle N.
    Rote, William E.
    Tang, Sydney C. W.
    Tesar, Vladimir
    Trachtman, Howard
    Trimarchi, Hernan
    Tumlin, James A.
    Wong, Muh Geot
    Perkovic, Vlado
    LANCET, 2023, 402 (10417): : 2077 - 2090
  • [47] Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
    Lafayette, Richard
    Kristensen, Jens
    Stone, Andrew
    Floege, Juergen
    Tesar, Vladimir
    Trimarchi, Hernan
    Zhang, Hong
    Eren, Necmi
    Paliege, Alexander
    Reich, Heather N.
    Rovin, Brad H.
    Barratt, J.
    LANCET, 2023, 402 (10405): : 859 - 870
  • [48] LONG-TERM EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS: 2-YEAR RESULTS FROM THE PHASE 3 SELECT-PSA 1 STUDY
    Mcinnes, I.
    Kato, K.
    Magrey, M.
    Merola, J. F.
    Kishimoto, M.
    Haaland, D.
    Chen, L.
    Duan, Y.
    Liu, J.
    Lippe, R.
    Wung, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 260 - 261
  • [49] INTRAVENOUS GOLIMUMAB INHIBITS RADIOGRAPHIC PROGRESSION AND MAINTAINS CLINICAL EFFICACY AND SAFETY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS DESPITE METHOTREXATE THERAPY: 2-YEAR RESULTS OF A PHASE 3 TRIAL OF INTRAVENOUS GOLIMUMAB
    Weinblatt, M. E.
    Bingham, C. O., III
    Mendelsohn, A. M.
    Kim, L.
    Lo, K. H.
    Noonan, L.
    Baker, D.
    Westhovens, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 939 - 939
  • [50] Saxagliptin Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease History or Cardiovascular Risk Factors: Results of a Pooled Analysis of Phase 3 Clinical Trials
    Cook, William
    Bryzinski, Brian
    Slater, Jill
    Frederich, Robert
    Allen, Elsie
    POSTGRADUATE MEDICINE, 2013, 125 (03) : 145 - 154
12345